International Clinical Trial: An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07832136) titled 'An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab' on Sept. 15.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Viridian Therapeutics, Inc.

Condition: Thyroid Eye Disease

Intervention: Drug: veligrotrug (LUMVOA™)

Recruitment Status: Not recruiting

Phase: Phase 4

Date of First Enrollment: September 2026

Target Sample Size: 30

Countries of Recruitment: United States

To know more, visit https://clinicaltria...